Day: September 17, 2025

HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 17.9.2025 AT 13:15 Huhtamaki’s financial reporting 2026In 2026, Huhtamaki will publish financial information as follows:Results 2025 February 13Annual report 2025 Week commencing March 2Interim Report, January 1-March 31, 2026 April 29Half-yearly Report, January 1-June 30, 2026 July 23Interim Report, January 1-September 30, 2026 October 29Huhtamaki observes a silent period prior to the publication of financial information. The silent period before publication of the 2025 Results is four weeks. The silent period before publication of the half-yearly report and interim reports starts after the end of the reporting period in question. Huhtamäki Oyj’s Annual General Meeting (AGM) is planned to be held on Wednesday, April 29, 2026. The Board of Directors will summon...

Press Release no. 07/2025 cBrain® supports Denmark’s largest-ever reforestation grant program with digital platform fully integrated with GIS Copenhagen, September 17, 2025 cBrain A/S (NASDAQ: CBRAIN) is proud to announce its role in supporting the Danish government’s historic Green Tripartite initiative, which launches today with Denmark’s largest-ever reforestation grant program. The program marks the start of a DKK 20 billion investment to plant 230,000 hectares of new forests, a key part of Denmark’s strategy to meet its climate goals. cBrain has delivered a complete digital grant management solution. The project was awarded in spring 2025, and the solution was developed and deployed in just four months, enabling landowners across Denmark to apply for reforestation grants quickly and easily. The solution is delivered using the cBrain...

Showcases include Panoramic Ultra-Large Virtual Display, All-Weather Drone Vision Systems, and AI-Powered Biometric Sensing to Redefine Next-Generation Defense and Aerospace Applications TAINAN, Taiwan, Sept. 17, 2025 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, and Liqxtal Technology Inc. (“Liqxtal”), a subsidiary of Himax dedicated to developing various image and optical solutions with exceptional adaptive optics design and manufacturing expertise, today announced a joint debut showcasing a comprehensive portfolio of next-generation imaging integration solutions designed to address critical needs in aerospace and defense applications at the Taipei Aerospace & Defense Technology Exhibition...

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin types New data show improved quality of life and decreased impact on families for investigational ZORYVE cream 0.05% in children aged 2–5 years with atopic dermatitis Data demonstrate both ZORYVE cream 0.3% and ZORYVE foam 0.3% improved signs and symptoms of plaque psoriasis in individuals with facial and/or genital involvementWESTLAKE VILLAGE, Calif. and PARIS, Sept. 17, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that new data on ZORYVE (roflumilast) efficacy across three common skin conditions—seborrheic dermatitis, atopic dermatitis, and psoriasis—will be presented at the...

GXO’s reverse logistics solutions have saved 160,000 journeys annually GXO and Greene King recycled or repurposed 16,000+ tonnes of waste in 2024 LONDON, U.K., Sept. 17, 2025 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, and Greene King, the UK’s leading pub company and brewer, today announced a series of sustainability achievements resulting from their long-standing partnership, which began in 2012, across a range of areas, notably fleet decarbonisation, waste reduction, recycling and community impact. “When a customer and logistics provider operate as true partners with a shared commitment to sustainability, great results follow,” said Chris Hyde, Managing Director – Food and Drink, GXO UK and Ireland. “GXO’s commitment to environmental sustainability combined...

Inside InformationGenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible for upfront and milestone payments of up to DKK 1.3 billion in addition to income from supplying GenSci with products. Partnership also aims to accelerate the introduction of a broader portfolio in China. Partnership is projected to become accretive to earnings margin in the medium term but is not expected to materially impact ALK’s revenue and earnings (EBIT) in 2025.ALK (ALKB:DC / OMX: ALK B) today announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical Co. Ltd. (“GenSci”) to develop and commercialise ALK’s house dust mite (“HDM”) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci is granted exclusive rights to ALK’s injectable Alutard® HDM product,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1993, AS AMENDED (THE “SECURITIES ACT”)) OR ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE US VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. NANTERRE (FRANCE)SEPTEMBER 17, 2025 FORVIA SUCCESSFULLY PRICES USD500 MILLION OF SENIOR NOTES DUE 2033 AND FURTHER DIVERSIFIES ITS INVESTOR BASE FORVIA has priced USD500 million in aggregate principal amount of 6.750% senior notes due 2033 (the “Notes”). This transaction is...

AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This funding will enable AecorBio to complete the investigational work of its lead peptide candidate FT-002a, in advanced prostate cancer, to enable an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2026. Filing the IND will represent a critical milestone, paving the way for AecorBio to transition FT-002a into clinical development, as a co-therapy in the management of advanced prostate cancer. FT-002a is a first-in-class peptide co-therapeutic for the treatment of advanced prostate cancer. Advanced prostate cancer affects more than 250,000 men annually in the U.S alone. Unlike conventional treatments,...

Frøya, 17 September 2025: In connection with issuance of new shares in Kaldvik AS (“Kaldvik” or the “Company”) as announced on 17 September 2025, Hege Dahl, a primary insider of the Company, and Larren Invest AS and AQON AS, being close associates to a primary insider of Kaldvik, have completed transactions in the Company’s shares as further specified in the attached notifications of trading. This information is subject to the disclosure requirements pursuant to article 19 of Regulation EU 596/2014 (MAR) and section 5-12 of the Norwegian Securities Trading ActAttachmentsKaldvik_PDMR_Larren Invest ASKaldvik_PDMR _Hege DahlKaldvik_PDRM_AQON AS